Publications
460 publications
- Date
- Relevance
-
Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...
-
GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
The National Health Care Institute has completed its assessment whether tafamidis (Vyndaqel®) for the treatment of wild-type or ...
-
Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy
Zorginstituut Nederland recommends that ataluren be designated as a potential candidate for conditional inclusion. Ataluren is ...
-
GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis
The National Health Care Institute has completed its assessment whether siponimod (Mayzent®) is interchangeable with a product ...
-
Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) in combination with obinutuzumab ...
-
GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
The National Health Care Institute has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of ...
-
GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
The National Health Care Institute has completed its assessment whether ozanimod (Zeposia®) for the treatment of adult patients ...
-
GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
The National Health Care Institute has completed its assessment whether amisulpride (Aktiprol®) can be included in the GVS. ...
-
Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
The National Health Care Institute has completed its assessment whether esketamine nasal spray (Spravato®) can be included in the ...
-
Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
The National Health Care Institute has completed its assessment whether trastuzumab-emtansine (Kadcyla®) can be included in the ...